X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs CIPLA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA CIPLA ABBOTT INDIA/
CIPLA
 
P/E (TTM) x 32.6 43.8 74.2% View Chart
P/BV x 8.1 3.6 224.9% View Chart
Dividend Yield % 0.8 0.4 232.5%  

Financials

 ABBOTT INDIA   CIPLA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
CIPLA
Mar-17
ABBOTT INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs6,015622 967.2%   
Low Rs3,707458 808.9%   
Sales per share (Unadj.) Rs1,236.9181.9 680.2%  
Earnings per share (Unadj.) Rs122.212.9 949.3%  
Cash flow per share (Unadj.) Rs129.029.3 440.0%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %0.70.4 194.4%  
Book value per share (Unadj.) Rs521.2155.7 334.8%  
Shares outstanding (eoy) m21.25804.51 2.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.93.0 132.3%   
Avg P/E ratio x39.842.0 94.8%  
P/CF ratio (eoy) x37.718.4 204.6%  
Price / Book Value ratio x9.33.5 268.8%  
Dividend payout %28.615.5 184.3%   
Avg Mkt Cap Rs m103,296434,516 23.8%   
No. of employees `0003.023.0 12.8%   
Total wages/salary Rs m3,37026,338 12.8%   
Avg. sales/employee Rs Th8,891.86,349.1 140.0%   
Avg. wages/employee Rs Th1,140.01,143.0 99.7%   
Avg. net profit/employee Rs Th878.3449.3 195.5%   
INCOME DATA
Net Sales Rs m26,284146,302 18.0%  
Other income Rs m5042,287 22.1%   
Total revenues Rs m26,789148,589 18.0%   
Gross profit Rs m3,66524,758 14.8%  
Depreciation Rs m14413,229 1.1%   
Interest Rs m81,594 0.5%   
Profit before tax Rs m4,01712,222 32.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4211,798 79.0%   
Profit after tax Rs m2,59610,354 25.1%  
Gross profit margin %13.916.9 82.4%  
Effective tax rate %35.414.7 240.5%   
Net profit margin %9.97.1 139.6%  
BALANCE SHEET DATA
Current assets Rs m14,44687,370 16.5%   
Current liabilities Rs m4,72533,081 14.3%   
Net working cap to sales %37.037.1 99.7%  
Current ratio x3.12.6 115.8%  
Inventory Days Days5187 59.1%  
Debtors Days Days2062 31.4%  
Net fixed assets Rs m1,113111,567 1.0%   
Share capital Rs m2131,609 13.2%   
"Free" reserves Rs m10,808123,645 8.7%   
Net worth Rs m11,076125,254 8.8%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m16,241209,532 7.8%  
Interest coverage x497.08.7 5,733.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.60.7 231.8%   
Return on assets %16.05.7 281.2%  
Return on equity %23.48.3 283.6%  
Return on capital %36.38.5 427.5%  
Exports to sales %0.634.2 1.8%   
Imports to sales %12.68.3 151.6%   
Exports (fob) Rs m16250,050 0.3%   
Imports (cif) Rs m3,32212,203 27.2%   
Fx inflow Rs m26851,066 0.5%   
Fx outflow Rs m3,92717,678 22.2%   
Net fx Rs m-3,65933,388 -11.0%   
CASH FLOW
From Operations Rs m2,51423,824 10.6%  
From Investments Rs m-800-13,127 6.1%  
From Financial Activity Rs m-803-13,239 6.1%  
Net Cashflow Rs m912-2,478 -36.8%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 7.9 12.2 64.8%  
FIIs % 0.1 23.7 0.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.1 26.2 65.3%  
Shareholders   18,270 161,166 11.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 200 Points Higher; Lupin & Axis Bank Top Gainers(09:30 am)

Majority of Asian stock indices are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.07%, while the Hang Seng is up 1.06%.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 22, 2017 11:01 AM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - MERCK LTD COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS